With the advent of new targeted treatments and immunotherapies, Quintiles has provided clinical services for over 700 phase 1 and phase 2 oncology studies since 2011.
The rapid advancement of immunotherapy in recent years has presented a number of challenges to pharmaceutical firms looking to monitor and measure efficacy in patients.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
